Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: A case-control study

Infection

Volumn 41, Issue 2, 2013, Pages 503-509

  Shilo, S ^a   Assous, M V ^a   Lachish, T ^a   Kopuit, P ^a   Bdolah Abram, T ^b   Yinnon, A M ^a   Wiener Well, Y ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Bacteriuria; Carbapenem resistance; Klebsiella pneumoniae; Multi drug resistance; Nosocomial infection; Urinary tract infection

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; CARBAPENEM; COLISTIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; BACTERIURIA; CASE CONTROL STUDY; CONTROLLED STUDY; DEMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; INVASIVE PROCEDURE; ISRAEL; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; RETROSPECTIVE STUDY; RISK FACTOR; SURGERY; URINARY CATHETER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTERIURIA; BETA-LACTAM RESISTANCE; CARBAPENEMS; CASE-CONTROL STUDIES; COLISTIN; CONFIDENCE INTERVALS; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; KAPLAN-MEIER ESTIMATE; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; URINARY CATHETERS; YOUNG ADULT;

EID: 84879502009     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0380-0     Document Type: Article

References (29)

1. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39:333-40.
2. Gona F, Mezzatesta ML, Corona D, Zerbo D, Scriffignano V, Stefani S, Veroux P, Veroux M. Klebsiella pneumoniae ESBL producers responsible for severe UTIs in a renal transplant unit. Infection. 2011;39:83-5.
3. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228-36.
4. Raveh D, Rudensky B, Huerta M, Aviv Y, Yinnon AM. Use of time-trend analysis in the design of empirical antimicrobial treatment of urinary tract infection. Eur J Clin Microbiol Infect Dis. 2003;22:158-64.
5. MacKenzie FM, Forbes KJ, Dorai-John T, Amyes SG, Gould IM. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet. 2007;350:783.
6. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother. 2006;50:3098-101.
7. Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis. 2006;12:1209-13.
8. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, Shalit I, Carmeli Y. Containment of a country-wide outbreak of carbapenem resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011;52:848-55.
9. Wiener-Well Y, Rudensky B, Yinnon AM, et al. Carriage rate of carbapenem-resistant Klebsiella pneumoniae in hospitalized patients during a national outbreak. J Hosp Infect. 2010;74:344-9.
10. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007;60:1124-30.
11. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2007;52:1028-33.
12. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18:54-60.
13. Kwak YG, Choi SH, Choo EJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist. 2005;11:165-9.
14. Cope M, Cevallos ME, Cadle RM, Darouiche RO, Musher DM, Trautner BW. Inappropriate treatment of catheter-associated asymptomatic bacteriuria in a tertiary care hospital. Clin Infect Dis. 2009;48:1182-8.
15. Bradford PA, Bratu S, Urban C. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis. 2004;39:55-60.
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 19th International supplement. CLSI document M100-S10. Wayne: Clinical Laboratory Standards Institute; 2009.
17. Henschke R, Yinnon AM, Rudensky B, Attias D, Raveh D. Assessment of the clinical significance of production of extended-spectrum-β-lactamase (ESBL) by Enterobacteriaceae. Infection. 2006;34:66-74.
18. Raveh D, Yinnon AM, Broide E, Rudensky B. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem, and piperacillin-tazobactam, with and without clavulanic acid. Chemotherapy. 2007;53:185-9.
19. Yinnon AM, Butnaru A, Raveh D, Jerassy Z, Rudensky B. Klebsiella bacteraemia: community versus nosocomial infection. Q J Med. 1996;89:933-41.
20. Bahagon Y, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Prevalence and predictive features of bacteremic urinary tract infection in emergency department patients. Eur J Clin Microbiol Infect Dis. 2007;26:349-52.
21. Marchi M, Grilli E, Mongardi M, Bedosti C, Nobilio L, Moro ML. Prevalence of infections in long-term care facilities: how to read it? Infection. 2012;40:493-500.
22. Burke JP. Nosocomial urinary tract infections. In: Mayhall CG, editor. Hospital epidemiology infection control. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 267-86.
23. Salgavo CD. Prevention of catheter associated urinary tract infection. In: Wenzel RP, editor. Prevention and control of nosocomial infections. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 297-311.
24. Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem resistant pneumonia bacteremia. Infect Control Hosp Epidemiol. 2009;30:972-6.
25. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099-106.
26. Kang CI, Kim SH, Kim DM, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2004;25:860-7.
27. Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol. 2010;31:620-6.
28. Carmeli Y, Akova M, Cornaglia G, et al. Controlling the spread of carbapenemase-producing Gram-negatives; therapeutic approach and infection control. Clin Microbiol Infect. 2010;16:102-11.
29. Miriagou V, Cornaglia G, Edelstein M, et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect. 2010;16:112-22.